ATH 0.00% 0.3¢ alterity therapeutics limited

Ann: Prana's PBT2 named one of Top Neuroscien, page-13

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 16,487 Posts.
    lightbulb Created with Sketch. 777
    re: Ann: Prana's PBT2 named one of Top Ne... For phase 2 $250m is high in my books , been doing some more research on other's who have done phase 3 trials and you do have to do them on a large number of patients so the expense it quite a lot more.

    Currently they are only doing 41 patients in their phase 2 trial which is not much. Others usually report positive results in phase 2 trials because of the low number of participants but when they do phase 3 with a lot more patients the results are often not that positive.

    In that interview there is no mention of what their intentions are with phase 3 , do it alone or partner with one of the majors. Shall watch with interest.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.000(0.00%)
Mkt cap ! $15.96M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $1.454K 484.7K

Buyers (Bids)

No. Vol. Price($)
73 107950070 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 271679 2
View Market Depth
Last trade - 16.10pm 01/11/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.